People who are sick, or in the case of very sick patients it would be their loved ones, still need to agree to enter a drug trial. With Leronlimab’ lack of media exposure, combined with more awareness of other drugs also available or in trials, one could reasonably assume that a majority of the patients entering CD12 are sicker, or further along in their illness. Because before that choice is made they were likely presented with, and treated with, more obvious options. When those treatments failed to work, everyone involved would be more willing to try the unknown option. For that reason I’m both hopeful and cautious about the results. If Leronlimab works like we think it should absolutely separate itself from placebo. But also if these patients are more like the Montefiore patients than the other EIND patients they’re more complicated and we may need to see full enrollment to make it clear how well Leronlimab works. Either way I’m beyond anxious to hear about the interim analysis and see what happens. My guess, based on nothing but gut, is that it’s good but we still need to hit full enrollment.